Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday as both companies submitted ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of ...

Pharma major CEO Mike Doustdar, on Friday, 31 October 2025, said that the company has notified its employees who have been ...

Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Shares of Hims & Hers Health ($HIMS) rallied on Tuesday after management said it’s in discussions with Novo Nordisk ($NVO) to ...

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.

The bidding war for US obesity focused biotech Metsera, which has attracted offers from Pfizer and Novo Nordisk , and ...

Danish pharma major Novo Nordisk today confirmed that it submitted an unsolicited proposal to acquire Metsera, aiming to ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United ...